JERRI BRACEY: Open Payments
NPI 1023625688 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,169 in 81 payments from 16 companies in 2025. Trend: 2023 $211 · 2024 $868 · 2025 $2,169
Food & beverage: $2,169
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 8 | $441 |
| Otsuka America Pharmaceutical, Inc. | 19 | $419 |
| ABBVIE INC. | 10 | $363 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $236 |
| Janssen Pharmaceuticals, Inc | 5 | $115 |
| Teva Pharmaceuticals USA, Inc. | 4 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $98 |
| Axsome Therapeutics, Inc. | 4 | $88 |
| Alkermes, Inc. | 3 | $72 |
| Lundbeck LLC | 3 | $56 |
Products named: INGREZZA, REXULTI, VRAYLAR, CAPLYTA, SPRAVATO, TRINTELLIX, Auvelity, AUSTEDO XR.
Industry payments across NV — which companies pay providers there.
